FY March 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)

Overview of Business Performance

Consolidated net sales for the third quarter of FY March 2026 were ¥164.01301 billion (3.5% YoY increase), with domestic sales at ¥100.19202 billion (0.9% YoY decrease) and overseas sales at ¥63.82 billion (11.3% YoY increase). Operating income was ¥9.134 billion (16.5% YoY decrease), ordinary income was ¥11.82 billion (12.0% YoY decrease), and net income attributable to owners of the parent for the quarter was ¥6.487 billion (21.2% YoY decrease). In Japan, declines in the acute care hospital market and reduced AED sales in the PAD market negatively impacted results, while overseas growth was driven by double-digit increases in North America, Europe, and Asia.

Outlook and Dividends

The full-year earnings forecast for FY March 2026 was revised to net sales of ¥235.0 billion (down ¥5.0 billion from previous forecast), operating income of ¥20.0 billion (down ¥4.0 billion), ordinary income of ¥22.0 billion (unchanged), and net income attributable to owners of the parent of ¥12.5 billion (unchanged). The annual dividend forecast was increased to ¥32 (previously ¥31). The assumed exchange rates from Q4 onwards are ¥154/USD and ¥184/EUR. The company will continue to focus on expanding consumables and services businesses and improving the quality of medical devices, aiming for growth overseas.